Lack of evidence of stimulatory autoantibodies to platelet‐derived growth factor receptor in patients with systemic sclerosis
Authors:
- 30 March 2009
- journal article
- systemic sclerosis-basic-science-studies
- Published by Wiley in Arthritis & Rheumatism
- Vol. 60 (4) , 1137-1144
Abstract
Objective: Systemic sclerosis (SSc) is a severe connective tissue disease of unknown etiology, characterized by fibrosis of the skin and multiple internal organs. Recent findings suggested that the disease is driven by stimulatory autoantibodies to platelet‐derived growth factor receptor (PDGFR), which stimulate the production of reactive oxygen species (ROS) and collagen by fibroblasts. These results opened novel avenues of research into the diagnosis and treatment of SSc. The present study was undertaken to confirm the presence of anti‐PDGFR antibodies in patients with SSc.Methods: Immunoglobulins from 37 patients with SSc were purified by protein A/G chromatography. PDGFR activation was tested using 4 different sensitive bioassays, i.e., cell proliferation, ROS production, signal transduction, and receptor phosphorylation; the latter was also tested in a separate population of 7 patients with SSc from a different research center.Results: Purified IgG samples from patients with SSc were positive when tested for antinuclear autoantibodies, but did not specifically activate PDGFRα or PDGFRβ in any of the tests. Cell stimulation with PDGF itself consistently produced a strong signal.Conclusion: The present results raise questions regarding the existence of agonistic autoantibodies to PDGFR in SSc.Keywords
This publication has 27 references indexed in Scilit:
- Transactivation of Src, PDGF receptor, and Akt is involved in IL‐1β‐induced ICAM‐1 expression in A549 cellsJournal of Cellular Physiology, 2007
- Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosisArthritis & Rheumatism, 2007
- Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo‐controlled phase I/II trial of CAT‐192Arthritis & Rheumatism, 2007
- Transforming growth factor-β signaling through the Smad proteins: Role in systemic sclerosisAutoimmunity Reviews, 2006
- Treatment of pulmonary fibrosis in systemic sclerosis: Light at the end of the tunnel?Arthritis & Rheumatism, 2006
- Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptorsArthritis & Rheumatism, 2004
- Receptor tyrosine kinase transactivation: fine-tuning synaptic transmissionTrends in Neurosciences, 2003
- Role of insulin receptor substrate‐2 in interleukin‐9‐dependent proliferationFEBS Letters, 2000
- Chimeric alpha- and beta-platelet-derived growth factor (PDGF) receptors define three immunoglobulin-like domains of the alpha-PDGF receptor that determine PDGF-AA binding specificity.Journal of Biological Chemistry, 1990
- Preliminary criteria for the classification of systemic sclerosis (scleroderma)Arthritis & Rheumatism, 1980